NEWS 
& MEDIA

MEDIA
CONTACT

Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.

If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com

For other Takeda news releases, please visit the Takeda.com Newsroom. 

GO TO TAKEDA NEWSROOM

NEWS
RELEASES

4/27/2021

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

READ MORE  
3/18/2021

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio

READ MORE  
1/28/2021

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

READ MORE